Xuanyuan Lu
Shaoxing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Nanomaterials in the diagnosis and therapy of osteoarthritis: current research advances and future clinical prospects.
Journal: Frontiers in bioengineering and biotechnology
Published: July 15, 2025
Enhanced osteoarthritis treatment using an injectable pH-responsive and cartilage-targeted liposome-anchored kartogenin-incorporated methacrylated gelatin hydrogel microspheres.
Journal: International journal of biological macromolecules
Published: March 02, 2025
Fangchinoline alleviates the progression of osteoarthritis through the nuclear factor kappa B signaling pathway.
Journal: Toxicology and applied pharmacology
Published: December 01, 2024
Selective STAT3 inhibitor STX-0119 alleviates osteoarthritis progression by modulating the STAT3/PPARγ signaling pathway.
Journal: Biochemical pharmacology
Published: April 05, 2024
Targeted inhibition of STAT3 (Tyr705) by xanthatin alleviates osteoarthritis progression through the NF-κB signaling pathway.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 13, 2023
Identification of key biomarkers for predicting CAD progression in inflammatory bowel disease via machine-learning and bioinformatics strategies.
Journal: Journal of cellular and molecular medicine
Published: September 28, 2023
Dual protective role of velutin against articular cartilage degeneration and subchondral bone loss via the p38 signaling pathway in murine osteoarthritis.
Journal: Frontiers in endocrinology
Published: April 23, 2022
Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo.
Journal: Drug design, development and therapy
Published: August 01, 2020
Galangin suppresses RANKL-induced osteoclastogenesis via inhibiting MAPK and NF-κB signalling pathways.
Journal: Journal of cellular and molecular medicine
Published: May 17, 2020
Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 26, 2020
Sotrastaurin, a PKC inhibitor, attenuates RANKL-induced bone resorption and attenuates osteochondral pathologies associated with the development of OA.
Journal: Journal of cellular and molecular medicine
Published: December 28, 2019
Last Updated: 09/26/2026